[Therapeutic effect of encapsulated into the nanocontainers MBP immunodominant peptides on EAE development in DA rats]
- PMID: 22997702
- DOI: 10.1134/s1068162012030144
[Therapeutic effect of encapsulated into the nanocontainers MBP immunodominant peptides on EAE development in DA rats]
Abstract
Multiple Sclerosis (MS) is a serve autoimmune neurodegenerative disease. Development of innovative approaches of MS treatment is of a high priority in the modern immunology and pharmacy. In the present study we showed high therapeutic efficiency of immunodominant peptides of myelin basic protein (MBP) incorporated into the monolayer mannosylated liposomes on the development of experimental autoimmune encephalomyelitis (EAE) in DA rats. MBP is a component ofoligodendrocytes' membrane, which form axonal sheath, and is one of the major autoantigens in MS. We analyzed binding pattern ofanti-MBP autoantibodies from MS patients using previously designed MBP epitope library. Utilizing the same approach we investigated pool of anti-MBP antibodies from SJL/J and C57/BL6 mice and DA rats with induced EAE. The most relevant rodent model to MS was EAE in DA rats according to the autoantibodies' binding pattern. We selected three immunodominant MBP fragments encapsulated in monolayer mannosylated liposomes for the following treatment of verified DA rodent model. MBP fragment 46-62 was the most effective in reducing of the first EAE attack, whereas MBP 124-139 and 147-160 inhibited development of pathology during remission stage. Simultaneous administration of these peptides in liposomes significantly decreased level of anti-MBP antibodies. Synergetic therapeutic effect of MBP fragments reduced integral disease score by inhibiting first EAE wave and subsequent remission, thus, our findings disclosure novel approaches for efficient treatment of Multiple Sclerosis.
Similar articles
-
Characterization of the antigen specificity and TCR repertoire, and TCR-based DNA vaccine therapy in myelin basic protein-induced autoimmune encephalomyelitis in DA rats.J Immunol. 2003 Jun 15;170(12):6371-8. doi: 10.4049/jimmunol.170.12.6371. J Immunol. 2003. PMID: 12794171
-
Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP(87-99) analogue and effects of cyclic peptides.Bioorg Med Chem. 2000 Aug;8(8):1903-9. doi: 10.1016/s0968-0896(00)00134-6. Bioorg Med Chem. 2000. PMID: 11003134
-
Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99.Int Immunol. 1998 Aug;10(8):1139-48. doi: 10.1093/intimm/10.8.1139. Int Immunol. 1998. PMID: 9723700
-
Major T-cell responses in multiple sclerosis.Mol Med Today. 1995 May;1(2):79-83. doi: 10.1016/s1357-4310(95)92366-7. Mol Med Today. 1995. PMID: 17607899 Review.
-
The ups and downs of EAE.Int Rev Immunol. 1993;9(4):277-85. doi: 10.3109/08830189309051211. Int Rev Immunol. 1993. PMID: 7683709 Review.
Cited by
-
Neurobehavioral burden of multiple sclerosis with nanotheranostics.Neuropsychiatr Dis Treat. 2015 Oct 15;11:2675-89. doi: 10.2147/NDT.S82768. eCollection 2015. Neuropsychiatr Dis Treat. 2015. PMID: 26508863 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous